Population structure and pharmacogenomic risk stratification in the United States

BMC Biology

Shashwat Deepali Nagar¹  I. King Jordan²  Andrew B. Conley² 

[1] School of Biological Sciences, Georgia Institute of Technology, Atlanta, GA, USA;PanAmerican Bioinformatics Institute, Cali, Colombia;School of Biological Sciences, Georgia Institute of Technology, Atlanta, GA, USA;PanAmerican Bioinformatics Institute, Cali, Colombia;IHRC-Georgia Tech Applied Bioinformatics Laboratory, 950 Atlantic Drive, 30332, Atlanta, GA, USA;

关键词: Population genomics;    Pharmacogenomics;    Precision public health;    Genetic ancestry;    Race;    Ethnicity;   

DOI  :  10.1186/s12915-020-00875-4

来源: Springer

【 摘 要 】

BackgroundPharmacogenomic (PGx) variants mediate how individuals respond to medication, and response differences among racial/ethnic groups have been attributed to patterns of PGx diversity. We hypothesized that genetic ancestry (GA) would provide higher resolution for stratifying PGx risk, since it serves as a more reliable surrogate for genetic diversity than self-identified race/ethnicity (SIRE), which includes a substantial social component. We analyzed a cohort of 8628 individuals from the United States (US), for whom we had both SIRE information and whole genome genotypes, with a focus on the three largest SIRE groups in the US: White, Black (African-American), and Hispanic (Latino). Our approach to the question of PGx risk stratification entailed the integration of two distinct methodologies: population genetics and evidence-based medicine. This integrated approach allowed us to consider the clinical implications for the observed patterns of PGx variation found within and between population groups.ResultsWhole genome genotypes were used to characterize individuals’ continental ancestry fractions—European, African, and Native American—and individuals were grouped according to their GA profiles. SIRE and GA groups were found to be highly concordant. Continental ancestry predicts individuals’ SIRE with > 96% accuracy, and accordingly, GA provides only a marginal increase in resolution for PGx risk stratification. In light of the concordance between SIRE and GA, taken together with the fact that information on SIRE is readily available to clinicians, we evaluated PGx variation between SIRE groups to explore the potential clinical utility of race and ethnicity. PGx variants are highly diverged compared to the genomic background; 82 variants show significant frequency differences among SIRE groups, and genome-wide patterns of PGx variation are almost entirely concordant with SIRE. The vast majority of PGx variation is found within rather than between groups, a well-established fact for almost all genetic variants, which is often taken to argue against the clinical utility of population stratification. Nevertheless, analysis of highly differentiated PGx variants illustrates how SIRE partitions PGx variation based on groups’ characteristic ancestry patterns. These cases underscore the extent to which SIRE carries clinically valuable information for stratifying PGx risk among populations, albeit with less utility for predicting individual-level PGx alleles (genotypes), supporting the concept of population pharmacogenomics.ConclusionsPerhaps most interestingly, we show that individuals who identify as Black or Hispanic stand to gain far more from the consideration of race/ethnicity in treatment decisions than individuals from the majority White population.

【 授权许可】

CC BY